In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
Opinion|Videos|November 18, 2024
Key Updates in Clinical Guidelines for CKD Testing in Patients With Type 2 Diabetes
Key Takeaways
- Early and regular CKD testing in type 2 diabetes patients is crucial for timely intervention and management.
- eGFR and UACR are recommended for comprehensive assessment of kidney function and damage.
Panelists discuss key updates in clinical guidelines for chronic kidney disease (CKD) testing in patients with type 2 diabetes, highlighting the latest recommendations for improving screening and diagnosis.
Advertisement
- What are the key updates in clinical guidelines for CKD testing in patients with type 2 diabetes?
Advertisement
Related to this article
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD
2
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
3
The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
4
AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD
5